Corporate ActionJul 31, 2026, 08:39 AM
Co-Diagnostics to raise $2.67M via warrant exercise, issues new warrants
AI Summary
Co-Diagnostics, Inc. entered into an inducement agreement with certain warrant holders to exercise existing warrants for 1,702,362 shares at $1.571 per share, generating approximately $2.67 million in gross proceeds. In consideration, the company will issue new common stock purchase warrants for up to 3,404,724 shares at an exercise price of $1.56, contingent on stockholder approval. Maxim Group LLC will serve as the exclusive placement agent, receiving a 7.0% cash fee and $50,000 for expenses. The net proceeds are intended for general corporate purposes.
Key Highlights
- Holders to exercise existing warrants for 1,702,362 shares at $1.571 each.
- Co-Diagnostics expects to receive $2.67 million gross proceeds from warrant exercise.
- Company to issue new warrants for 3,404,724 shares at $1.56 exercise price.
- New warrants require stockholder approval per Nasdaq rules before being exercisable.
- Maxim Group LLC to receive 7.0% cash fee and $50,000 for expenses as placement agent.
- Net proceeds from the transaction will be used for general corporate purposes.
- Company will file a registration statement for the resale of the new warrant shares.
Price Impact
More from CODX